Raymond James analyst Reni Benjamin attributes the selloff today in shares of Therapeutics to “stale” vadadustat safety concerns. After speaking with management the analyst views the selloff as an overreaction.
https://thefly.com/landingPageNews.php?id=2887649
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.